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ABSTRACT 
 
The aim of this work was to study the plasma concentration of IL-6 by ELISA in the patients with mood disorders 
and normal healthy donors. The plasma concentration of IL-6 was higher in the patients than in the control healthy 
group. Results suggested that IL-6 could serve as an immunological marker in mood disorder pathogenesis as well. 
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INTRODUCTION 
 
Numerous interactions of the immune system with 
the central nervous system (CNS) have been 
described over the the past few years.Therefore, a 
wide heterogeneity of results can be observed in 
immunological studies of severe depression 
(Muller and Ackenheil, 1998). Cytokines play an 
important role in the different phases of the 
immune response. The continuous advances in the 
knowledge of the pathophysioloy of chronic 
disorders, combined with the progress of 
radiochemistry, have led to the development of 
new specific radiolabelled agents for the imaging 
of chronic diseases (Signore et al, 2002). 
The finding that depression often co-exists with 
some subclinical autoimmune diseases, such as 
thyroiditis and lupus, suggests that depression may 
cause alterations in the immune system, or that in 
fact it is an autoimmune disorder itself. It is known 
that acute stress may initiate a transient, protective 
immunological response. Therefore, prolonged or 
poorly controlled psychosocial stressors may result 
in changes in different components of the immune 
system, mainly cytokines, such as INFalfa, INF 
gamma, IL-1 and IL-6 (Fountoulakis et al., 2004). 
The IL-6 has been described over the past few 
years as an important factor involved in a wide 
range of psychiatric disorders.  
Interleukin 6 (IL-6) is a pleiotropic cytokine, 
which is released from different blood cell types. 
One function of IL-6 is to activate B cells to 
synthesize the antibodies (Plata-Salaman, 1991). 
However, like other cytokines, IL-6 is not only 
synthesized and released by the immune cells of 
the peripheral blood, but also produced by the 
activated astrocytes and microglia cells in the 
central nervous system (CNS). Several findings 
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suggest that IL-6 may mediate the exacerbation of 
autoimmune disorders in the CNS (Dunn, 1992).  
The IL-6 can be involved in the differentiation of 
B lymphocytes, local IgG synthesis in the CNS, 
and blood-brain barrier disturbance (Frei et all., 
1989). In the hypothalamus, IL-6 can induce the 
release of growth hormone releasing hormone and 
TSH, and it stimulates in vitro the secretion of 
prolactin and growth hormone from the pituitary 
cells (Spangelo et al., 1989). 
A strong relationship between the IL-6 and 
neurotransmitter production has been reported in 
various studies. IL-6 can stimulate neurons in vitro 
to secrete dopamine and probably other 
catecholamines (Hama et al., 1991). The 
peripheral application of IL-6 in the animal 
experiments was shown to enhance the 
dopaminergic and serotoninergic turnover in the 
hippocampus and frontal cortex, without affecting 
noradrenaline (Zalcman et al., 1994). Conversely, 
noradrenaline can stimulate astrocytes to release 
IL-6 (Dunn, 1992). Both observations point to a 
direct influence of activating cytokines, especially 
IL-6, on the catecholaminergic neurotransmitter 
system. The present work aimed to study the effect 
of the concentration of the IL-6 in mood disorder 
patients and normal healthy donors. 
 
 
MATERIALS AND METHODS 
  
Subjects  
The subjects included 30 patients with mood 
disorders, of both the genders, ranging in age from 
18 to 68 years and 30 healthy volunteers as 
controls, also of both the genders ranging in age 
from 18 to 55 years. The Human Ethics 
Committee of Universidade Estadual de Londrina 
approved the present work (CEP 120/01, 
Resolução 196/96-CNS), and the subjects signed a 
written informed consent to be included in the 
present study. Peripheral blood samples were 
obtained from the patients and control subjects. 
The patients and control subjects were seen at the 
Ambulatory Service of Psychiatry, Hospital de 
Clínicas, Universidade Estadual de Londrina, 
Londrina, PR, Brazil, during the period of 2001 to 
2003. All the subjects, patients and controls were 
submitted to clinical evaluation according to the 
Structured Clinical Interview for DSM-IV axis I 
disorder – clinic version SCID-CV, translated into 
Portuguese (Del-Ben et al., 2001). 
 
Blood sampling and measurement of plasma 
levels of IL-6 
Venous blood was collected and plasma was 
obtained by centrifugation at 2000 x g for 10 min 
and kept frozen at - 20°C until assayed. The IL-6 
levels were measured by using the human 
interleukin-6 (IL-6) ELISA system, RPN 274 
(Amersham Pharmacia, Biotech, UK) according to 
the manufacturer’s instructions.  All the assays 
were carried out at the same time and in one run. 
The plate was read in a microplate 
spectrophotometer (Reader Sanofi Diagnostic 
Pasteur PR 2100, USA) at 490nm. 
 
Statistical analysis 
Plasma IL-6 levels in the patients and normal 
healthy donors were compared by Student’s t-test 
using Micronal Origin 4.1 Statistic Program, with 
the level of significance set at p<0.05. 
 
 
RESULTS AND DISCUSSION 
 
This work compared plasma IL-6 levels of the 
control group (normal healthy subjects) with 
patients with depression. The mean plasma IL-6 
level of depressive subjects (1.75 pg/ml) was 
significantly higher than in the normal donor 
subjects (0.2 pg/ml; p<0.05) (Figure 1). 
It has been shown that IL-6 can be higher in the 
depression patients when compared to the healthy 
subjects (Frommenberger et al., 1997; Lin et al., 
1998; Schlatter et al. 2004). The present results 
were, therefore, compatible with the previous 
findings. Table 1 shows the concentration of IL-6 
reported by many authors. 
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Figure 1 - Quantification of plasma IL-6 in patients and healthy donors. The cytokine was 
quantified using the human interleukin-6 (IL-6) ELISA system, RPN 2754 (Amersham Pharmacia, 
Biotech UK). * The plasma concentration of IL-6 was significantly different higher in patients than 
in the control group (p<0.05). (Origin 4.1) 
 
 
Table 1 - Comparison of concentration of IL-6 in different types of disorders. 
 
 
Controversy remains over the influence of 
psychotic drugs, where many investigations have 
reported a decrease in the plasma IL-6 levels as a 
result of anti-psychotic treatment (for example, 
Maes et al., 1995). However, Kubera et al. (2004) 
found increased plasma levels of IL-6 in the 
patients undergoing antidepressant treatment 
(imipramine, venlafaxine, 5-HTP and fluoxetine). 
The results showed that even the patients treated 
with different types of drugs had an increase in the 
plasma IL-6. 
A large body of evidence suggests that immune 
system dysregulation is associated with major 
depressive disorder in adults. Findings from 
Gabbaya et al (2009) suggest that immune system 
dysregulation may be associated with the 
adolescent major depressive disorder, with an 
imbalance of Th1/Th2 shifted toward Th1, as 
documented in adult major depressive disorder. 
There was a trend towards the increased IL-6 
plasma levels in the adolescents with major 
depressive disorder compared to controls. Forti et 
al (2010) found that the baseline IL-6 and ACT 
(1–antichymotrypsin) were increased in prevalent 
major depression and relevant depressive 
symptoms.  
Some findings suggest that serum IL-6 levels may 
be especially high in the patients with an 
unfavorable course of disease (Lin et al., 1998; 
Frommberger et al., 1997).  The increased plasma 
levels of IL-6 in those psychiatric patients seemed 
to be related to the clinical course, especially 
changes to psychotic symptoms such as delusions 
or disorganized thinking.  
It is also believed (although not well documented) 
that the production of proinflammatory cytokines 
(such as IL-1, IL-6, INFalfa, INFgamma), whether 
in the context of therapeutic administration or 
medical illness, could induce the symptoms that 
closely resemble major depression (Raison et al., 
2002). These observations allowed to infer that the 
increased production of proinflammatory 
Year Author IL-6 Situation or Approach 
1995 Maes et al. Lower Anti-psychotic treatment 
1997 Frommberger et al. Higher Depression and schizophrenic patients 
1998 Lin et al. Higher Schizophrenic patients 
2001 Musselman et al. Higher Major depression in cancer patients 
2002 Ushiroyama, et al. Higher Menopausal women with and without depression 
2004 Schlatter et al. Higher Major depression 
2004 Kubera et al. Higher Antidepressant treatment 
2009 Gabbaya et al. Higher Major depression 
2010 Forti et al. Higher Major depression 
2010 Podlipný et al. Lower Self-reported depression 
2010 O’Donovan et al. Higher Anxious individuals 
Control Patients
0,0
0,5
1,0
1,5
2,0
2,5
IL
-
6 
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cytokines might play a crucial role in the immune 
and acute phase response in the depression 
(Fountoulakis, et al. 2004).  
Higher than normal plasma IL-6 concentrations 
were associated with a diagnosis of major 
depression in cancer patients. IL-6 may contribute 
to symptoms that overlap with those seen in major 
depression (Musselman et al., 2001).  
The association between the depressed mood and 
serum level of IL-6 has already been described as 
significantly stronger in men than in women 
(Penninx et al., 2003). Ushiroyama, et al. (2002) 
observed elevated plasma interleukin-6 (IL-6) and 
soluble IL-6 receptor concentrations in 
menopausal women with and without depression. 
A typical finding, which has been replicated 
several times and supports the inflammatory 
hypothesis of depression, is the elevation of blood 
pro-inflammatory cytokines such as interleukin 
(IL)-1, IL-6 and tumor necrosis factor-α (TNF-α) 
in the patients suffering from depression. Study 
from Podlipný et al (2010) compared the levels of 
interleukin (IL)-6, IL-8, IL-10 and tumor necrosis 
factor-α (TNF-α) in the population samples 
characterized by a high or low level of self-
reported depression. The authors found that the IL-
6 serum level in the people with symptoms of 
depression was lower. However, the difference 
was on the border of statistical significance. 
Depressive symptoms, poor sleep quality, and 
systemic markers of inflammation (IL-6) are 
frequently associated (Prather et al., 2009) 
It is known that the influence of neuroleptic 
medications cannot be ignored because the doses 
of neuroleptics are not fixed after the admission. 
There are several observations showing that the 
antipsychotic therapy with neuroleptics is 
accompanied by a functional decrease in the IL-6 
system. Wichers and Maes (2002) reported on the 
psychoneuroimmuno-pathophysiology of 
cytokine-induced depression in humans. A 
significant decrease of IL-6 during therapy with 
neuroleptics was described by Maes and 
coworkers (1995). On the other hand, Kubera et al. 
(2004) reported a stimulatory effect of 
antidepressants on the production of IL-6 in a 
study involving the patients with treatment-
resistant depression. 
Previous studies have suggested that the regulation 
of the proinflammatory cytokine interleukin (IL)-6 
is abnormal in the patients with major depression. 
Carpenter and collaborators (2004) conducted a 
study to determine whether IL-6 concentrations in 
cerebrospinal fluid (CSF) differed between the 
depressed patients and healthy control subjects. 
Their findings failed to support the notion that 
immune activation could be causally involved in 
the pathogenesis of depression.  
Negative emotions such as anxiety and depression 
confer increased risk for the disorders with an 
inflammatory etiology, and elevated inflammatory 
activity may be an important mediator of emotion–
disease relationships. Data from O’Donovan et al 
(2010) indicate that clinically anxious individuals 
have lower morning cortisol and elevated IL-6 
compared with non-anxious individuals, 
highlighting a potential pathway by which anxiety 
may increase the risk for inflammatory diseases. 
This suggests that the anxiety may be associated 
with inflammatory activity independent of 
depression and neuroticism, thus, indicating 
specificity in relationships between the negative 
emotions and biological responses.  
Evidence has been presented that examined the 
cytokine link to depression. There may be no 
common molecular mechanism underlying all the 
depression. Variables such as stress, cytokine 
immune response, and medical illness probably 
have bidirectional causality. Proinflammatory 
cytokines interfere with the body’s feedback loop 
to reduce the circulating corticosteroids during the 
stress response. Patients with depression have been 
found to have an activated inflammatory response 
(Wilson et al., 2008). 
Selective serotonin reuptake inhibitors and 
serotonin noradrenaline reuptake inhibitors are 
generally considered first-line treatments for the 
depression. However, it has been reported by 
Yoshimura et al (2009) that 30–40% of all 
depressive patients who receive a sufficient dose 
and duration of antidepressant treatment fail to 
respond. The plasma levels of IL-6 and TNF-α 
were significantly higher in the depressed patients 
than in the healthy controls. These results could 
suggest that higher plasma IL-6 activity was 
associated with the refractoriness of depression, 
and plasma IL-6 levels might be a predictor for the 
response to selective serotonin reuptake inhibitor 
or serotonin noradrenaline reuptake inhibitor.  
Significant evidence suggests that the immune 
system is capable of profoundly affecting the 
central nervous system, functioning in ways that 
may contribute to the development and expression 
of neuropsychiatric disorders, including 
depression. It appears that plasma IL-6 
concentrations can play a role in the diagnosis of 
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schizophrenic patients. The present results 
suggested that IL-6 could serve as an 
immunological marker in mood disorder 
pathogenesis as well. 
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